Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Best practice in precision medicine for prostate cancer

Dr Elena Castro, Dr Pasquale Rescigno, Prof Gert Attard and Dr Axel Heidenreich
Best practice in precision medicine for prostate cancer ( Dr Elena Castro, Dr Pasquale Rescigno, Prof Gert Attard and Dr Axel Heidenreich )
21 Oct 2025

Visugromab plus nivolumab significantly increases pathologic response in muscle-invasive bladder cancer

Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy
Visugromab plus nivolumab significantly increases pathologic response in muscle-invasive bladder cancer ( Prof Andrea Necchi -  The Vita-Salute San Raffaele University, Milan, Italy )
20 Oct 2025

ESMO 2025: Bladder cancer highlights

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina
ESMO 2025: Bladder cancer highlights ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )
20 Oct 2025

ESMO 2025: Prostate highlights

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina
ESMO 2025: Prostate highlights ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )
20 Oct 2025

ESMO 2025: Renal highlights

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina
ESMO 2025: Renal highlights ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )
20 Oct 2025

Sacituzumab tirumotecan improves progression-free and overall survival in EGFR-TKI resistant NSCLC

Dr Li Zhang - Sun Yat-sen University Cancer Center, Guangzhou, China
Sacituzumab tirumotecan improves progression-free and overall survival in EGFR-TKI resistant NSCLC ( Dr Li Zhang - Sun Yat-sen University Cancer Center, Guangzhou, China )
20 Oct 2025

Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors

Dr Javier C Cortés - Hospital Ruber Internacional, Madrid Spain
Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors ( Dr Javier C Cortés - Hospital Ruber Internacional, Madrid Spain )
20 Oct 2025

177Lu-PSMA-617 in metastatic castration-resistant prostate cancer shows higher PSA response with lower toxicity

Dr Kim Nguyen Chi - BC Cancer, British Columbia, Canada
177Lu-PSMA-617 in metastatic castration-resistant prostate cancer shows higher PSA response with lower toxicity ( Dr Kim Nguyen Chi - BC Cancer, British Columbia, Canada )
20 Oct 2025

Perioperative enfortumab vedotin plus pembro improves survival and pCR in cisplatin-ineligible MIBC

Prof Christof Vulsteke - Maria Middelares General Hospital, Ghent, Belgium
Perioperative enfortumab vedotin plus pembro improves survival and pCR in cisplatin-ineligible MIBC ( Prof Christof Vulsteke - Maria Middelares General Hospital, Ghent, Belgium )
19 Oct 2025

Avelumab maintenance after reduced chemotherapy cycles improves QoL without sacrificing survival in aUC

Dr Enrique Grande - MD Anderson Cancer Center Madrid, Madrid, Spain
Avelumab maintenance after reduced chemotherapy cycles improves QoL without sacrificing survival in aUC ( Dr Enrique Grande - MD Anderson Cancer Center Madrid, Madrid, Spain )
19 Oct 2025

Trastuzumab deruxtecan improves disease-free survival vs trastuzumab emtansine in high-risk HER2+ early breast cancer

Dr Charles E. Geyer - University of Pittsburgh School of Medicine, Pittsburgh, USA
Trastuzumab deruxtecan improves disease-free survival vs trastuzumab emtansine in high-risk HER2+ early breast cancer ( Dr Charles E. Geyer - University of Pittsburgh School of Medicine, Pittsburgh, USA )
19 Oct 2025

Non-clear cell renal cell carcinoma: Management of papillary RCC

Prof Camillo Porta and Prof Laurence Albiges
Non-clear cell renal cell carcinoma: Management of papillary RCC ( Prof Camillo Porta and Prof Laurence Albiges )
7 Oct 2025